Tuberculosis (TB) remains a major global health threat with ~1.5 million deaths annually. Global elimination of TB is hampered by the lack of an effective vaccine. BCG is currently the only licenced TB vaccine but its efficacy is limited especially in adults.
Two new Fellows were inducted into the University of Cape Town’s (UCT) prestigious College of Fellows at the annual fellows dinner held at Smuts Hall this week. In addition, six College of Fellows Young Researcher Awards were made.
University of Cape Town (UCT) academics Dr Shahieda Adams and Professor Mohamed Jeebhaywere part of a team that played an integral role in providing technical medical input to the legal arguments in South Africa’s historic R5-billion settlement for the gold miners who contracted silicosis and/or pulmonary tuberculosis (TB) at work.
Working on some of the most important breakthroughs in tuberculosis (TB) diagnostics globally, and testing HIV and TB vaccines, is a vital part of the pioneering work being done at the Khayelitsha-based Wellcome Centre for Infectious Diseases Research in Africa (CIDRI-Africa).
People living with HIV who are hospitalized at the time tuberculosis is diagnosed are at high risk of death, even after starting antituberculosis treatment. Charlotte Schutz and members of the CIDRI-Africa team studied a group of patients to find out why.
Dr Ying Zhao’s MMed study is entitled “Improved treatment outcomes with bedaquiline when substituted for second-line injectable agents in multidrug resistant tuberculosis”. Her MMed is supervised by Dr Sean Wasserman and Professor Graeme Meintjes.